Premiering on Lifetime TV!

This extended 30-minute “Special Edition” of The Balancing Act Presents Behind the Mystery of Dravet Syndrome will first air on June 13 at 7:30am ET/PT, with a repeat showing June 21 at 7:30am ET/PT on Lifetime TV. It will then be available to stream online at: https://thebalancingact.com/rare.

Hosted by Montell Williams and Olga Villaverde, the segment follows the Raia family and the medical journey of their daughter, Kaylee. A clinical overview of Dravet syndrome is presented by Kaylee’s neurologist, Dr. Linda Laux, an Attending Physician in the Neurology and Epilepsy Center of the Ann & Robert H. Lurie Children’s Hospital, as well as an Associate Professor of Pediatrics at Northwestern University Feinberg School of Medicine. Dr. Laux also serves as the DSF Medical Advisory Board Chair. 

During the segment, Nicolas Coudurier, CEO of Biocodex, and Mary Anne Meskis, Executive Director of DSF, discuss the importance of partnerships between industry and patient organizations to assure that new medications arriving on the market meet the needs of people with rare diseases.

Premiering on Lifetime TV!

This extended 30-minute “Special Edition” of The Balancing Act Presents Behind the Mystery of Dravet Syndrome will first air on June 13 at 7:30am ET/PT, with a repeat showing June 21 at 7:30am ET/PT on Lifetime TV. It will then be available to stream online at: https://thebalancingact.com/rare.

Hosted by Montell Williams and Olga Villaverde, the segment follows the Raia family and the medical journey of their daughter, Kaylee. A clinical overview of Dravet syndrome is presented by Kaylee’s neurologist, Dr. Linda Laux, an Attending Physician in the Neurology and Epilepsy Center of the Ann & Robert H. Lurie Children’s Hospital, as well as an Associate Professor of Pediatrics at Northwestern University Feinberg School of Medicine. Dr. Laux also serves as the DSF Medical Advisory Board Chair. 

During the segment, Nicolas Coudurier, CEO of Biocodex, and Mary Anne Meskis, Executive Director of DSF, discuss the importance of partnerships between industry and patient organizations to assure that new medications arriving on the market meet the needs of people with rare diseases.